Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Sangamo Therapeutics has received a consensus recommendation of "Moderate Buy" from six research firms, with an average 1-year target price of $4.50.
• The company reported a loss of ($0.08) EPS for the most recent quarter, below analysts' expectations of ($0.07), with revenues of $18.31 million against estimates of $31.68 million.
• Approximately 56.92% of Sangamo Therapeutics' stock is owned by institutional investors and hedge funds, indicating significant interest from larger financial entities.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six research firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $4.50.

A number of equities research analysts have commented on the stock. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a report on Thursday, September 4th. Wall Street Zen upgraded shares of Sangamo Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th.

Sangamo Therapeutics Trading Up 0.2%

NASDAQ:SGMO opened at $0.67 on Thursday. The stock has a market capitalization of $203.53 million, a price-to-earnings ratio of -2.33 and a beta of 1.21. The firm has a fifty day simple moving average of $0.55 and a two-hundred day simple moving average of $0.59. Sangamo Therapeutics has a 12 month low of $0.41 and a 12 month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The company had revenue of $18.31 million during the quarter, compared to analyst estimates of $31.68 million. Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%. Equities analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SGMO. R Squared Ltd acquired a new position in shares of Sangamo Therapeutics during the second quarter valued at about $28,000. Cerity Partners LLC grew its holdings in shares of Sangamo Therapeutics by 439.2% during the first quarter. Cerity Partners LLC now owns 55,000 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 44,800 shares during the last quarter. Caption Management LLC acquired a new position in shares of Sangamo Therapeutics during the first quarter valued at about $37,000. XTX Topco Ltd acquired a new position in shares of Sangamo Therapeutics during the second quarter valued at about $41,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Sangamo Therapeutics during the first quarter valued at about $47,000. 56.92% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.